Impaired brca2 function in cells and non-human transgenic animals
CA 2301871 A1 · Owner: Lexicon Genetics Incorporated · Inventors: Hasty, Paul; Donoho, Greg
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
ScRad51, a member of the RAD52 epistasis group in Saccharomyces cerevisiae is , a major component in the recombinational repair pathway employed to repair genetic damage caused by ionizing radiation. The mouse homologue of ScRad51 MmRad51, appears to have a similar function; however the precise mechanism of , action is not well understood. For ScRad51 protein:protein associations are , critical for function. Therefore the yeast two-hybrid system was used to isolate proteins that associate with MmRad51 to better understand recombinational repair in mammalian cells and mouse Brca2 was isolated. In humans, BRCA2, is a tumor suppressor gene important in the etiology of breast cancer. A …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 25, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 25, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 25, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.